Immunogenic peptides from the HPV E7 protein
The invention provides immunogenic peptides from the HPV type 16 E7 protein that comprise overlapping class I restricted T cell epitopes. Also disclosed are methods of administering DNA molecules encoding these peptides to a host mammal.
1. A substantially pure peptide less than 19 amino acids in length, wherein the peptide comprises the amino sequence Leu Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys (SEQ ID NO:16).
2. A substantially pure peptide less than 19 amino acids in length, wherein the peptide comprises the amino acid sequence Gly Thr Leu Gly Ile Val Cys Pro Ile (SEQ ID NO:2 1).
3. The peptide of claim 2 , wherein the peptide's sequence comprises Xaa Gly Thr Leu Gly Ile Val Cys Pro Ile Cys, Xaa being Met, Ala, Ser, Arg, Lys, Gly, Gln, Asp, or Glu (SEQ ID NO:25).
4. The peptide of claim 2 , wherein the peptide's sequence comprises Met Gly Ile Val Cys Pro Ile Cys (SEQ lID NO:26).
5. The peptide of claim 3 , wherein the peptide's sequence consists of Xaa Gly Thr Leu Gly Ile Val Cys Pro Ile Cys, Xaa being Met, Ala, Ser, Arg, Lys, Gly, GIn, Asp, or Glu.
6. The peptide of claim 4 , wherein the peptide's sequence consists of Met Gly Thr Leu Gly Ile Val Cys Pro Ile Cys Ser Gln Lys (SEQ ID NO: 26).
7. A substantially pure peptide consisting of the amino acid sequence Thr Leu Gly Ile Val Cys Pro Ile (SEQ ID NO:20).
8. A therapeutic composition comprising:
(a) the peptide of claim 1 , and
(b) a pharmaceutically acceptable carrier.
9. A therapeutic composition comprising:
(a) the peptide of claim 2 , and
(b) a pharmaceutically acceptable carrier.